406 related articles for article (PubMed ID: 29705704)
21. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y
Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479
[TBL] [Abstract][Full Text] [Related]
22. FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition.
Li R; Okada H; Yamashita T; Nio K; Chen H; Li Y; Shimakami T; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955438
[TBL] [Abstract][Full Text] [Related]
23. TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop.
Park TJ; Kim JY; Oh SP; Kang SY; Kim BW; Wang HJ; Song KY; Kim HC; Lim IK
Hepatology; 2008 May; 47(5):1533-43. PubMed ID: 18393292
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive clinicopathological significance and putative transcriptional mechanisms of Forkhead box M1 factor in hepatocellular carcinoma.
Wu HY; Luo LF; Wei F; Jiang HM
World J Surg Oncol; 2023 Nov; 21(1):366. PubMed ID: 38001498
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.
Huang X; Qin J; Lu S
Int J Clin Exp Pathol; 2015; 8(2):1515-24. PubMed ID: 25973036
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
[TBL] [Abstract][Full Text] [Related]
27. Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.
Chand V; Pandey A; Kopanja D; Guzman G; Raychaudhuri P
Mol Cancer Res; 2019 May; 17(5):1063-1074. PubMed ID: 30814128
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.
Shang R; Wang M; Dai B; Du J; Wang J; Liu Z; Qu S; Yang X; Liu J; Xia C; Wang L; Wang D; Li Y
Mol Oncol; 2020 Jun; 14(6):1381-1396. PubMed ID: 32174012
[TBL] [Abstract][Full Text] [Related]
29. XTP8 promotes hepatocellular carcinoma growth by forming a positive feedback loop with FOXM1 oncogene.
Han M; Lu H; Han K; Yuan X; Liu S; Wang Y; Zhao J; Liang P; Cheng J
Biochem Biophys Res Commun; 2019 Jul; 515(3):455-461. PubMed ID: 31164201
[TBL] [Abstract][Full Text] [Related]
30. Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells.
Yan D; Yan X; Dai X; Chen L; Sun L; Li T; He F; Lian J; Cai W
Oncol Rep; 2019 Aug; 42(2):785-796. PubMed ID: 31233189
[TBL] [Abstract][Full Text] [Related]
31. FOXM1 augments sorafenib resistance and promotes progression of hepatocellular carcinoma by epigenetically activating KIF23 expression.
Zhu C; Guo H; Ma Z; Shi S; Zhao X; Zhai D; Zhou X; Jiang P; Xu Q; Cai J
Biochem Biophys Res Commun; 2023 May; 656():1-9. PubMed ID: 36940637
[TBL] [Abstract][Full Text] [Related]
32. LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression.
Wei Y; Wang Z; Zong Y; Deng D; Chen P; Lu J
Biomed Pharmacother; 2020 May; 125():109890. PubMed ID: 32106369
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro.
Wu QF; Liu C; Tai MH; Liu D; Lei L; Wang RT; Tian M; Lü Y
Acta Pharmacol Sin; 2010 Mar; 31(3):361-6. PubMed ID: 20154714
[TBL] [Abstract][Full Text] [Related]
34. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma.
Yang YF; Pan YH; Cao Y; Fu J; Yang X; Zhang MF; Tian QH
Oncotarget; 2017 Jul; 8(29):47195-47205. PubMed ID: 28525379
[TBL] [Abstract][Full Text] [Related]
35. FoxM1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by targeting Snai1.
Yu CP; Yu S; Shi L; Wang S; Li ZX; Wang YH; Sun CJ; Liang J
Mol Med Rep; 2017 Oct; 16(4):5181-5188. PubMed ID: 28849004
[TBL] [Abstract][Full Text] [Related]
36. Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma.
Qu K; Xu X; Liu C; Wu Q; Wei J; Meng F; Zhou L; Wang Z; Lei L; Liu P
Cancer Lett; 2013 Apr; 331(1):105-14. PubMed ID: 23262037
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
38. Isovitexin reduces carcinogenicity and stemness in hepatic carcinoma stem-like cells by modulating MnSOD and FoxM1.
Cao X; Liu L; Yuan Q; Li X; Cui Y; Ren K; Zou C; Chen A; Xu C; Qiu Y; Quan M; Zhang J; Cao J; Chen X
J Exp Clin Cancer Res; 2019 Jun; 38(1):264. PubMed ID: 31208440
[TBL] [Abstract][Full Text] [Related]
39. USP39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo.
Yuan X; Sun X; Shi X; Jiang C; Yu D; Zhang W; Guan W; Zhou J; Wu Y; Qiu Y; Ding Y
Oncol Rep; 2015 Aug; 34(2):823-32. PubMed ID: 26081192
[TBL] [Abstract][Full Text] [Related]
40. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
